BFRI Form 4: Director Beth Hoffman Receives 20,000 Options (07/22/2025)

Rhea-AI Filing Summary

Beth J. Hoffman, a director of Biofrontera Inc. (BFRI), was granted an employee stock option on 07/22/2025 to buy 20,000 shares of common stock at an exercise price of $1.00 per share. The option becomes exercisable in monthly installments beginning August 22, 2025 and vests over twelve equal monthly installments; the option expires on July 22, 2035. The Form 4 was signed by an attorney-in-fact on September 16, 2025. The filing reports the grant as a direct beneficial ownership of 20,000 underlying shares.

Positive

• Grant recorded clearly: The Form 4 discloses 20,000 employee stock options with exercise price and vesting schedule.
• Vesting schedule specified: Options vest in twelve equal monthly installments beginning August 22, 2025.

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Director received a time‑based option grant aligning her compensation with long‑term stock performance.

The filing documents a standard employee stock option awarded to a board director: 20,000 options exercisable at $1.00 with a ten‑year term and a 12‑month vesting schedule starting in August 2025. This is a routine equity-based grant intended to link the director's incentives to shareholder value over a multi-year horizon. The disclosure is clear on exercise price, quantity, vesting commencement, and expiration; no other compensation terms or cash transactions are reported.

Securities Analyst

TL;DR: Transaction is a non‑derivative disclosure of option-based rights to acquire 20,000 shares; impact appears routine.

The Form 4 indicates a grant categorized under derivative securities (employee stock option) with 20,000 underlying common shares and an exercise price of $1. The options vest monthly over one year starting August 22, 2025, and expire July 22, 2035. The report shows direct beneficial ownership of the underlying shares post‑grant. There are no reported dispositions, cash proceeds, or unusual terms disclosed in this filing.

09/16/2025 - 09:17 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Hoffman Beth J.

(Last) (First) (Middle)

120 PRESIDENTIAL WAY SUITE 330

(Street)

WOBURN MA 01801

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Biofrontera Inc. [ BFRI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$1	07/22/2025		A		20,000		(1)	07/22/2035	Common Stock	20,000	$0	20,000(2)	D

Explanation of Responses:

1. The option vests in twelve equal monthly installments beginning on August 22, 2025.

2. Options with different terms are not included.

	/s/ Daniel Hakansson, Attorney-in-fact for Beth J. Hoffman	09/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Beth J. Hoffman report on the Form 4 for BFRI?

The Form 4 reports a grant of an employee stock option for 20,000 shares with an exercise price of $1.00 per share.

When was the transaction for the BFRI Form 4 executed?

The transaction date reported is 07/22/2025 and the Form 4 was signed by an attorney‑in‑fact on 09/16/2025.

What are the vesting and expiration terms of the options in the BFRI filing?

The option vests in twelve equal monthly installments beginning August 22, 2025 and expires on July 22, 2035.

What is the exercise price and how many shares are underlying the option?

The exercise (conversion) price is $1.00 and the option covers 20,000 underlying common shares.

Does the Form 4 show any dispositions or sales by the reporting person?

No. The filing discloses an acquisition/award of options and does not report any dispositions or sales.